Dipyridamole thallium 201 imaging. How safe is it?

Pharmacology of 2-cyclohexylmethylidenehydrazinoadenosine (WRC-0470), a novel, short-acting adenosine A2A receptor agonist that produces selective coronary vasodilation

“…The most commonly observed side effects are chest pain, dyspnea and facial flushing [Cerqueira et al, 1994]. Previous clinical studies have shown that the adenosine-induced chest pain can be dissociated from ischemic pain [Beller, 1990] and can be abolished by prior administration of the A 1 -ADO receptor selective antagonist, N-0861 [Bertolet et al, 1996], demonstrating that the adenosine-induced chest pain in humans is due to activation of A 1 -ADO receptors. Because WRC-0470 is a weak agonist at the A 1 -ADO receptor it is predicted that chest pain would not occur at the doses of WRC-0470 that would be required to produce maximum dilation of the coronary blood vessels in the human.…”